Cell Therapy

News

Kymriah is first CAR-T cleared for follicular lymphoma in EU

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

News

Nkarta leaps on early CAR-NK data in blood cancers

Shares in Nkarta more than doubled yesterday on the results of early-stage clinical that suggested it could be on to a winner with its natural kill (NK) cell therapy platform.

Events

Partner Content

3rd Gamma Delta T Therapies Summit

The Only Industry-Specific Event on γδT Therapies

News

Bayer backs KRAS TCR player Affini-T in $175m financing

Bayer's venture capital unit has co-led a $175 million investment in Affini-T that will be used to take its T cell receptor (TCR) therapies for cancer cells with mutations like KRAs and p53

News

BMS cuts $3.15bn deal with Century for cancer cell therapies

Bristol-Myers Squibb chief executive Giovanni Caforio has promised to invest in the company's pipeline at the virtual JP Morgan Healthcare Conference, and demonstrated that commitment by li

News

Milestone as EMA starts review of Atara's 'off-the-shelf' ce...

Atara Biotherapeutics' tabelecleucel (tab-cel) has become the first 'allogeneic' cell therapy – in other words one which doesn't involve harvesting cells from patients – to be evaluated by

Kymriah is first CAR-T cleared for follicular lymphoma in EU

Nkarta leaps on early CAR-NK data in blood cancers

3rd Gamma Delta T Therapies Summit

Bayer backs KRAS TCR player Affini-T in $175m financing

BMS cuts $3.15bn deal with Century for cancer cell therapies

Milestone as EMA starts review of Atara's 'off-the-shelf' ce...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Cell Therapy

Editor's Picks